Comparing Tonix Pharmaceuticals Holding Corp. (TNXP) and Echo Therapeutics (ECTE)

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) and Echo Therapeutics (NASDAQ:ECTE) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitabiliy, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Volatility and Risk

Tonix Pharmaceuticals Holding Corp. has a beta of 2.83, suggesting that its share price is 183% more volatile than the S&P 500. Comparatively, Echo Therapeutics has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500.

Profitability

This table compares Tonix Pharmaceuticals Holding Corp. and Echo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals Holding Corp.	N/A	-107.33%	-97.16%
Echo Therapeutics	N/A	N/A	216.11%

Analyst Recommendations

This is a summary of current recommendations and price targets for Tonix Pharmaceuticals Holding Corp. and Echo Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals Holding Corp.	0	3	1	0	2.25
Echo Therapeutics	0	0	0	0	N/A

Tonix Pharmaceuticals Holding Corp. currently has a consensus price target of $7.50, indicating a potential upside of 103.25%. Given Tonix Pharmaceuticals Holding Corp.’s higher probable upside, research analysts clearly believe Tonix Pharmaceuticals Holding Corp. is more favorable than Echo Therapeutics.

Insider and Institutional Ownership

17.5% of Tonix Pharmaceuticals Holding Corp. shares are owned by institutional investors. 4.0% of Tonix Pharmaceuticals Holding Corp. shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Tonix Pharmaceuticals Holding Corp. and Echo Therapeutics’ revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	EBITDA	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals Holding Corp.	N/A	N/A	-$29.87 million	($11.25)	-0.33
Echo Therapeutics	N/A	N/A	N/A	($1.48)	-0.03

Tonix Pharmaceuticals Holding Corp. is trading at a lower price-to-earnings ratio than Echo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Tonix Pharmaceuticals Holding Corp. beats Echo Therapeutics on 5 of the 8 factors compared between the two stocks.

Echo Therapeutics Company Profile

Echo Therapeutics, Inc. is a medical device company. The Company is engaged in developing a non-invasive, wireless continuous glucose monitoring (CGM) system with use in the wearable-health consumer market, diabetes outpatient market and in the hospital setting. The Company operates through the development of transdermal skin permeation and diagnostic medical devices segment. The Company has also developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, enhanced delivery of topical pharmaceuticals and other applications. The CGM System includes a skin preparation device, transdermal glucose sensor, battery and wireless transmitter. The Company has conducted several human feasibility clinical studies with its CGM System in healthy subjects, diabetics and critically ill patients, as well as a clinical study at several hospitals in the United States.